Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$24.58 USD

24.58
38,100,621

0.00 (0.00%)

Updated Aug 11, 2025 04:00 PM ET

After-Market: $24.60 +0.02 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (68 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sweta Killa headshot

Rally in Travel and Tourism ETFs Set to Continue

by Sweta Killa

The solid trend in travel and tourism ETFs are likely to continue heading into the holiday season given the reopening of domestic and international borders for traveling.

Zacks Equity Research

Stock Market News for Nov 8, 2021

by Zacks Equity Research

Benchmarks closed higher on Friday lifted by solid October jobs report and encouraging COVID-19 antiviral drug results from Pfizer.

Nalak Das headshot

Three Encouraging News on U.S. Economic Recovery: 5 Top Picks

by Nalak Das

We have narrowed down our search to five large-cap growth stocks that have strong growth potential for the rest of 2021. These are: TSLA, NUE, ON, IT and CBRE.

Zacks Equity Research

Nektar (NKTR) Q3 Earnings Top, Pipeline Remains On Track

by Zacks Equity Research

Nektar (NKTR) reports mixed third-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.

Zacks Equity Research

Nonfarm Payrolls Jump in October

by Zacks Equity Research

Nonfarm Payrolls Jump in October.

Zacks Equity Research

Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.

Mark Vickery headshot

Huge Jobs Number: 531K, 4.6% Unemployment; Did Pfizer Cure Covid?

by Mark Vickery

The private sector alone brought 604K jobs, more than a third of which came from the Leisure & Hospitality and Professional & Business Services sectors.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Nucor, Dow, Pfizer, Costco and Lowe's

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Nucor, Dow, Pfizer, Costco and Lowe's

Zacks Equity Research

Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for USMC

Zacks Equity Research

Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Corcept's (CORT) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company tightens its revenue guidance for 2021.

Nalak Das headshot

Fed Chair Speaks in Cautious Tone Despite Tapering: 5 Picks

by Nalak Das

Each of our large-cap picks carries either a Zacks Rank #1 (Strong Buy) or 2 (Buy) and has a VGM Score of A. These are: NUE, PFE, DOW, COST and LOW.

Zacks Equity Research

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PFE vs. LLY: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (PFE) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y

by Zacks Equity Research

Amarin's (AMRN) reports lower sales volume for its drug, Vascepa, in the United States during the third quarter. The company's stock falls in pre-market trading.

Zacks Equity Research

Better-Than-Expected Private Payrolls in October

by Zacks Equity Research

Better-Than-Expected Private Payrolls in October.

Mark Vickery headshot

ADP: 571K New Private-Sector Jobs, Better than Expected

by Mark Vickery

571K new private-sector jobs in October surpassed the analyst estimate of 398K by a ton.

Zacks Equity Research

Stock Market News for Nov 3, 2021

by Zacks Equity Research

Wall Street maintained its northbound journey on Tuesday with all three major stock indexes closed at record-high levels for three consecutive days.

Zacks Equity Research

Exelixis (EXEL) Misses on Q3 Earnings & Revenues, Tweaks View

by Zacks Equity Research

Exelixis (EXEL) misses on earnings and revenues in the third quarter. Both figures increase on a year-over-year basis.

Nalak Das headshot

5 Blue-Chip Stock to Buy as Dow Crosses a Fresh Milestone

by Nalak Das

We have narrowed down our search to five Dow stocks with strong growth potential for the ensuing quarter. These are: CVX, DOW, MCD, HD and MSFT.

Zacks Equity Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Zacks Equity Research

Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q3 Earnings

by Zacks Equity Research

Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2022 on the third-quarter earnings call.

Zacks Equity Research

Fed Set to Start Vital FOMC Meeting

by Zacks Equity Research

Fed Set to Start Vital FOMC Meeting.

Zacks Equity Research

Pfizer (PFE) Q3 Earnings Top, COVID Vaccine Drives 2021 View Up

by Zacks Equity Research

Pfizer (PFE) beats third-quarter estimates for earnings and sales, and lifts guidance for 2021.

Mark Vickery headshot

Fed Meets, Tapering in Our Midst; Pfizer Beats in Q3

by Mark Vickery

The question now is: when will the Fed start tapering, and by how much?

Zacks Equity Research

Pfizer (PFE) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of 24.07% and 7.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?